We have located links that may give you full text access.
Clinical Trial
Journal Article
Randomized Controlled Trial
Review
Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
Seminars in Oncology 2003 Februrary
Rituximab shows high single-agent activity in both previously untreated and relapsed or refractory indolent non-Hodgkin's lymphoma. In combination with chemotherapy, rituximab has achieved response rates higher than 90% with long duration of remission in phase II studies. Therefore, randomized phase III studies have been undertaken to determine whether rituximab plus chemotherapy can significantly improve outcomes compared with conventional chemotherapy in indolent non-Hodgkin's lymphoma. A study by the German Low-Grade Study Group has evaluated rituximab in combination with FCM (fludarabine/cyclophosphamide/mitoxantrone) in a randomized setting versus FCM alone in patients with relapsed or refractory follicular, mantle cell, or lymphoplasmacytic lymphoma. An interim analysis of 94 evaluable patients has shown a significantly higher response rate for rituximab plus FCM (overall response rate [ORR] 83%; complete response [CR] 35%) compared with FCM alone (ORR 58%; CR 13%), with no increase in toxicity. Superiority of rituximab plus FCM was seen in both follicular lymphoma (n = 53; ORR 92% v 75%; CR 40% v 21%) and, most strikingly, in mantle cell lymphoma (n = 38; ORR 65% v 33; CR 35% v 0%). A trend towards longer overall and disease-free survival for rituximab plus FCM has been observed, but longer follow-up is required.
Full text links
Related Resources
Trending Papers
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.Endocrine Reviews 2024 April 28
The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association.Circulation 2024 April 26
Intravenous infusion of dexmedetomidine during the surgery to prevent postoperative delirium and postoperative cognitive dysfunction undergoing non-cardiac surgery: a meta-analysis of randomized controlled trials.European Journal of Medical Research 2024 April 19
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Management of Diverticulitis: A Review.JAMA Surgery 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app